175137-38-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate is used as a chemical intermediate for the preparation of pyrazolylisoxazoles, which are compounds with potential applications in the development of drugs targeting IL-17, a protein involved in the immune system and associated with various inflammatory and autoimmune diseases.
As an intermediate in the synthesis of pyrazolylisoxazoles, Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate plays a crucial role in the development of new therapeutic agents that can potentially modulate the activity of IL-17, offering novel treatment options for patients suffering from conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis.

InChI:InChI=1/C11H7FN2S/c12-8-3-1-7(2-4-8)10-5-9(14)11(6-13)15-10/h1-5H,14H2

Upstream product

• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 100-63-0 phenylhydrazine 
• 267243-86-7 2-dimethylaminomethylidene-4,4,4-trifluoro-3-oxobutyrate ethyl ester 
• 371-14-2 4-fluorophenylhydrazine 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 

Downstream Products

• 1391943-57-9 3-(2-chloro-6-fluorophenyl)-5-(1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole 
• 618070-62-5 1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 1082827-27-7 [1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]acetic acid 

Relevant academic research and scientific papers

Method for synthesizing 1-substituted phenyl-5-trifluoromethyl (difluoromethyl)-4-pyrazole carboxylic acid

The invention relates to a method for synthesizing 1-substituted phenyl-5-trifluoromethyl (difluoromethyl)-4-pyrazole carboxylic acid. The method is as follows: performing a ring-forming reaction of phenylhydrazine or substituted phenylhydrazine with inte

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.